BJDXBJDXHealthcare · Medical Devices

BJDX Stock Forecast: Bluejay Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.74
−3.34% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 17 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.9M
Ticker Nerd rank
17/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.3M
Net income−$2.3M
Free cash flow−$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−33.3%
1M
−35.2%
YTD
−83.7%
1Y
−91.4%
From 52W high
−92.5%
From 52W low
0.0%
$2
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
17/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
68
Volatility
55
Issuance
30
Momentum
27
Growth
25
Quality
20
Revisions
20
Value
2

Accruals (68): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BJDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26BJDX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2023Dawson JamesDowngradeNeutral—
12 Jan 2022Dawson JamesInitiatesBuy$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BJDX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BJDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Bluejay Diagnostics, Inc. returned −91.4% against +6.9% for the S&P 500, dividends included.

BJDX vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26BJDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BJDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 93% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−138.1%

Higher than 10% of US stocks

Return on assets
−68.2%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bluejay Diagnostics, Inc. has a market value of $1.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$7.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$6.2M.

  • Shares outstanding: 1.0M.

  • Trailing P/E: 0.5×.

  • Bluejay Diagnostics, Inc. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

BJDX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
BJDXBluejay Diagnostics, Inc.$1.9M17
NUWENuwellis, Inc.$1.8M18
PFSAProfusa, Inc.$1.8M19
VVOSVivos Therapeutics, Inc.$1.8M43
AMIXAutonomix Medical, Inc.$1.7M31
ADGMAdagio Medical Holdings, Inc.$1.7M24
IVFINVO Fertility, Inc.$2.1M29

Take a look at BJDX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BJDX

How does Ticker Nerd's model rank BJDX?

As at 21 Nov 2026, Bluejay Diagnostics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (68 of 100).

What is the BJDX stock forecast for 2030?

No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.

How has BJDX stock performed over the past year?

Bluejay Diagnostics, Inc. returned -91.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bluejay Diagnostics, Inc. do?

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions.

Company

About Bluejay Diagnostics, Inc.

Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions. The company’s current product development includes the Symphony IL-6 test for monitoring disease progression in critical care, along with additional assays targeting myocardial infarction and congestive heart failure. Bluejay Diagnostics also develops point-of-care diagnostic products designed to give healthcare providers faster, practical insights at the bedside. Headquartered in Acton, Massachusetts, Bluejay Diagnostics Inc. serves the healthcare market through technologies aimed at improving diagnostic workflows and supporting informed clinical decision-making.

CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com